 In 2018, tofacitinib was approved for treatment of moderately to severely active ulcerative colitis in the United States, the first oral medication indicated for long term use in this condition.The evidence on methotrexate does not show a benefit in producing remission in people with ulcerative colitis.Off-label use of drugs such as cyclosporin and tacrolimus has shown some benefits.